Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine

Brain

Volumn 121, Issue 7, 1998, Pages 1231-1237

  May, A ^a,c,d   Shepheard, S L ^b   Knorr, M ^c   Effert, R ^c   Wessing, A ^c   Hargreaves, R J ^b   Goadsby, P J ^a   Diener, H C ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Fluorescein angiography; Migraine attack; Neurogenic inflammation; Plasma extravasation; Trigeminovascular system

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; ALBUMIN; FLUORESCEIN; INDOCYANINE GREEN; SUMATRIPTAN;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CLUSTER HEADACHE; DURA MATER; EXTRAVASATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RETINA;

EID: 0031867882     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.7.1231     Document Type: Article

References (58)

1. Bates D. Treatment with subcutaneous sumatriptan during the migraine aura [abstract]. Cephalalgia 1993; 13 Suppl 13: 188.
2. Bischoff PM, Flower RW. Ten years experience with choroidal angiography using indocyanine green dye: a new routine examination or an epilogue? Doc Ophthalmol 1985; 60: 235-91.
3. Brändli P, Löffler BM, Breum V, Osterwalder R, Maire JP, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 1996; 64: 315-22.
4. Bryant HU, Nelson DL, Button D, Cole HW, Baez MB, Lucaites VL, et al. A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci 1996; 59: 1259-68.
5. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-6.
6. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251-8.
7. Buzzi MG, Carter WB, Shimizu T, Heath H 3d, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991a; 30: 1193-200.
8. Buzzi MG, Moskowitz MA, Peroutka SJ, Byun B. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol 1991b; 103: 1421-8.
9. Connor HE, O'Shaughnessy CT. Effect of sumatriptan on sensory neurotransmission in guinea-pig basilar artery [abstract]. Cephalalgia 1993; 13 (Suppl 13): 42.
10. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, et al. Naratriptan: biological profile in animal models relevant to migraine [see comments]. Cephalalgia 1997; 17: 145-52. Comment in: Cephalalgia 1997; 17: 143.
11. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, et al. Naratriptan: biological profile in animal models relevant to migraine [see comments]. Cephalalgia 1997; 17: 145-52. Comment in: Cephalalgia 1997; 17: 143.
12. Couch JR Jr, Saper J, Meloche JP. Treatment of migraine with BMS180048: response at 2 hours. Headache 1996; 36: 523-30.
13. Critchley M. The mechanism and treatment of migraine. Practitioner 1934; 133: 54-61.
14. Cushing H. Surgery of the head. In: Keen WW, editor. Surgery: its principle and practice. Philadelphia: W.B. Saunders; 1908. p. 17-26.
15. Diener HC, for the RPR100893-201 Migraine Study Group. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In: 6th International Headache Research Seminar; Nov 17-19, 1995, Copenhagen, Denmark. 1995.
16. Feniuk W, Humphrey PP, Watts AD. Presynaptic inhibitory action of 5-hydroxytryptamine in dog isolated saphenous vein. Br J Pharmacol 1979; 67: 247-54.
17. Flower RW. Injection technique for indocyanine green and sodium fluorescein dye angiography of the eye. Invest Ophthalmol 1973; 12: 881-95.
18. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
19. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994; 117: 427-34.
20. Goldstein DJ, Wang O. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study [abstract]. Cephalalgia 1997; 17: 245.
21. Gupta P, Brown D, Butler P, Ellis P, Grayson KL, Land GC, et al. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 1995; 116: 2385-90.
22. Gupta P, Brown D, Butler P, Closier MD, Diekinson RP, Ellis P, et al. Preclinical in vivo pharmacology of eletriptan (UK-116,044): a potent and selective partial agonist at the '5HT1D-like' receptor [abstract]. Cephalalgia 1996; 16: 386.
23. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalagia 1988; 8 (Suppl 7): 1-96.
24. Hodge JV, Dollery CT. Retinal soft exudates. A clinical study by colour and fluorescence photography. QJ Med 1964; 33: 117-31.
25. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119: 1419-28.
26. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993; 109: 788-92.
27. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960; 10: 107-11.
28. Lance JW, Anthony M, Hinterberger H, The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967; 7: 93-102.
29. Lange K, Boyd LJ. Use of fluorescein method in establishment of diagnosis and prognosis of peripheral vascular diseases. Archs Intern Med 1944; 74: 175-84.
30. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993; 626: 303-5.
31. Lee WS, Moussaoui SM, Moskowitz MA. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 1994; 112: 920-4.
32. Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X, et al. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995; 116: 1661-7.
33. Lim JI, Flower RW. Indocyanine green angiography. [Review], Int Ophthalmol Clin 1995; 35: 59-70.
34. Limmroth V, Wermelskirchen D, Tegtmeier F, Diener HC. R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of 5HT1D-receptors [abstract]. Neurology 1997; 48 (3 Suppl 2): A69.
35. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987; 7: 4129-36.
36. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988; 8: 83-91.
37. Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barren VJ, Buckingham J, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997; 121: 157-64.
38. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996; 67: 375-8.
39. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16; 157-68.
40. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.[Review]. Trends Pharmacol Sci 1992; 13: 307-11.
41. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. [Review]. Neurology 1993; 43 (6 Suppl 3): S16-20.
42. Nielsen NV. The normal fundus fluorescein angiogram. V. Intraobserver-, interobserver- and interocular variation of the fundus fluorescein angiogram. Acta Ophthalmol (Copenh) 1985; 63: 463-6.
43. Nissila M, Parkkola R, Sonninen P, Salonen R. Intracerebral arteries and gadolinium enhancement in migraine without aura [abstract]. Cephalalgia 1996; 16: 363.
44. Panzardi G, Donati MC, Longobardi G, Poggi P. Choroidal angiography with indocyanine green dye: absorption and fluorescence techniques. Eur J Ophthalmol 1992; 2: 83-5.
45. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Archs Surg 1940; 41: 813-56.
46. Rodella A. Migraine and cutaneus vessels. [German]. Schweiz Med Wschr 1931; 61: 1256.
47. Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, et al. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials [abstract]. Cephalalgia 1997; 17: 245.
48. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988; 24: 732-7.
49. Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ. The non-peptide neurokinin 1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 1993; 108: 11-2.
50. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 1995; 34: 255-61.
51. Strassmann A, Mason P, Moskowitz M, Maciewicz R. Response of brainstem trigeminal neurons to electrical stimulation of the dura. Brain Res 1986; 379: 242-50.
52. Verheyen A, Vlaminckx E, Lauwers F, Borgers M, Wouters L. Radioactive colloidal gold as a tool to quantify extravasation of macromolecules in the rat cremaster muscle. Int J Microcirc Clin Exp 1987; 5: 321-33.
53. Welch KM, Barkley GL, Tepley N, Ramadan NM. Central neurogenic mechanisms of migraine. [Review]. Neurology 1993; 43 (6 Suppl 3): S21-5.
54. Wessing A. Fluoreszenzangiographie der Retina. Lehrbuch und Atlas. Stuttgart: Georg Thieme Verlag; 1968.
55. Wessing A. Principles of diagnostic progress through fluorescence angiography. [German]. Ber Zusammenkunft Dtsch Ophthalmol Ges 1975; 73: 566-8.
56. Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 1997; 328: 61-4.
57. Wolff HG, editor. Headache and other head pain. 2nd ed. New York: Oxford University Press; 1963.
58. Yocca FD, Gylys JA, Smith DW, Ruediger E, Yevich JP, Mahle C, et al. BMS-181885: a clinically effective migraine abortive with peripherovascular and neuronal 5HT1D antagonist properties [abstract]. Cephalalgia 1997; 17: 404.